New Report: Psychedelics 2021: Free 100-Page PDF Now Available Published By Psilocybin Alpha

• A deep dive into psychedelic drug policy reform efforts and successes in 2021, with a focus on key jurisdictions including the U.S. and Canada.
• A look at key research and clinical trials that were published in 2021, with analysis of themes like microdosing and SSRI interactions.
• Coverage of investments into both public and private psychedelics ventures in 2021, with thematic analysis and a look at key company highlights.
• An overview of psychedelics in popular culture last year, plus a discussion of just two controversies that erupted in 2021.
• In the final section we share the key trends we will be following as we look ahead to 2022.

There’s no two ways about it: this is a text-heavy long-read: apologies in advance for those that prefer their media diet to be a little more visual. But, readers should find light relief in the occassional chart, graph and case study.

A note from the Editor…

This report was great fun to write, and reminded me of just how much happened in the past year. We tried to maintain a balanced view, with a primary focus on research and trials as well as drug policy reform and other contextual factors. That doesn’t mean this report doesn’t contain opinions, though – that would be boring.

This series wouldn’t have been possible without the research support provided by Noah Smith. I’m also particularly (and eternally) grateful to our Pharmaceutical Advisor Michael Haichin and Editor-at-Large Graham Pechenik. And, thank you to all those that provided exclusive comments for this report.

Please feel free to forward this email, the DocSend link, and/or a PDF copy to anyone you feel would enjoy the report. I only ask that you refrain from editing the PDF without permission.

It’s a real privilege to be able to write independently, and to reach such a diverse and accomplished audience such as yourselves. The biggest privilege, however, is hearing your thoughts, comments and criticisms of the work we produce.

So please, don’t be shy: reply to this email and let me know what you thought of this report series.

With best wishes,
Josh Hardman
Founder, Editor